As on Wednesday, Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) got off with the flyer as it spiked 5.81% to $1.64, before settling in for the price of $1.55 at the close. Taking a more long-term approach, ZNTL posted a 52-week range of $1.01-$4.44.
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was -12.89%. Meanwhile, its Annual Earning per share during the time was -12.89%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 7.24%. This publicly-traded company’s shares outstanding now amounts to $72.14 million, simultaneously with a float of $58.17 million. The organization now has a market capitalization sitting at $118.30 million. At the time of writing, stock’s 50-day Moving Average stood at $1.5674, while the 200-day Moving Average is $1.7060.
Zentalis Pharmaceuticals Inc (ZNTL) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Biotechnology industry. Zentalis Pharmaceuticals Inc’s current insider ownership accounts for 19.37%, in contrast to 73.34% institutional ownership. According to the most recent insider trade that took place on Apr 30 ’25, this organization’s Director bought 21,000 shares at the rate of 1.40, making the entire transaction reach 29,373 in total value, affecting insider ownership by 281,192. Preceding that transaction, on Feb 06 ’25, Company’s Chief Medical Officer bought 20,000 for 2.28, making the whole transaction’s value amount to 45,656. This particular insider is now the holder of 36,629 in total.
Zentalis Pharmaceuticals Inc (ZNTL) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.48 per share during the current fiscal year.
Zentalis Pharmaceuticals Inc’s EPS increase for this current 12-month fiscal period is 7.24% and is forecasted to reach -2.07 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 8.39% through the next 5 years, which can be compared against the -12.89% growth it accomplished over the previous five years trading on the market.
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Trading Performance Indicators
Let’s observe the current performance indicators for Zentalis Pharmaceuticals Inc (ZNTL). It’s Quick Ratio in the last reported quarter now stands at 7.99. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 4.40.
In the same vein, ZNTL’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -2.28, a figure that is expected to reach -0.53 in the next quarter, and analysts are predicting that it will be -2.07 at the market close of one year from today.
Technical Analysis of Zentalis Pharmaceuticals Inc (ZNTL)
Through scrutinizing the latest numbers posted by the [Zentalis Pharmaceuticals Inc, ZNTL], it can be observed that its last 5-days Average volume of 0.65 million was lower the volume of 1.14 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 56.06% While, its Average True Range was 59.17.
Raw Stochastic average of Zentalis Pharmaceuticals Inc (ZNTL) in the period of the previous 100 days is set at 55.43%, which indicates a major fall in contrast to 78.26% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 0.0992 that was lower than 0.1056 volatility it exhibited in the past 100-days period.
